Adenovirus News and Research

RSS
Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.

Further Reading

Structural differences between SARS-CoV-1 and SARS-CoV-2 RBDs

Structural differences between SARS-CoV-1 and SARS-CoV-2 RBDs

13 Apr 2022
Air surveillance of SARS-CoV-2 and other respiratory pathogens

Air surveillance of SARS-CoV-2 and other respiratory pathogens

4 Apr 2022
Newcastle disease virus-based trivalent vaccine found to be effective across SARS-CoV-2 variants in mice

Newcastle disease virus-based trivalent vaccine found to be effective across SARS-CoV-2 variants in mice

29 Mar 2022
Clinical outcomes of SARS-CoV-2 coinfection with influenza viruses, respiratory syncytial virus, or adenoviruses

Clinical outcomes of SARS-CoV-2 coinfection with influenza viruses, respiratory syncytial virus, or adenoviruses

29 Mar 2022
Breast milk components show potent in vitro SARS-CoV-2 inhibition

Breast milk components show potent in vitro SARS-CoV-2 inhibition

24 Mar 2022
New device based on concert hall acoustics enables noninvasive, ultrasound brain treatments

New device based on concert hall acoustics enables noninvasive, ultrasound brain treatments

23 Mar 2022
New approach could lead to quicker generation of effective, personalized cancer vaccines

New approach could lead to quicker generation of effective, personalized cancer vaccines

22 Mar 2022
BNT162b2 booster vaccination induces robust humoral and cellular immune responses

BNT162b2 booster vaccination induces robust humoral and cellular immune responses

17 Mar 2022
The immunogenicity of homologous and heterologous boosters in adults who received inactivated COVID-19 vaccine six months prior

The immunogenicity of homologous and heterologous boosters in adults who received inactivated COVID-19 vaccine six months prior

17 Mar 2022
Do anti-nucleocapsid antibodies affect COVID-19 immune reactions?

Do anti-nucleocapsid antibodies affect COVID-19 immune reactions?

15 Mar 2022
Clinical trial of novel rabies vaccine in human volunteers begins in Tanzania

Clinical trial of novel rabies vaccine in human volunteers begins in Tanzania

9 Mar 2022
Omicron-based vaccine candidate generated to assess whether immunogenicity could be further improved

Omicron-based vaccine candidate generated to assess whether immunogenicity could be further improved

8 Mar 2022
Current progress in SARS-CoV-2 vaccine candidates

Current progress in SARS-CoV-2 vaccine candidates

7 Mar 2022
Diabetes and the mTOR pathway in COVID-19 patients

Diabetes and the mTOR pathway in COVID-19 patients

6 Mar 2022
Serological test to assess presence of immunoglobulin isotypes targeted against antigens routinely used in COVID-19 diagnosis

Serological test to assess presence of immunoglobulin isotypes targeted against antigens routinely used in COVID-19 diagnosis

2 Mar 2022
Recombinant adenovirus vector vaccine generates mucosal antibodies against SARS-CoV-2

Recombinant adenovirus vector vaccine generates mucosal antibodies against SARS-CoV-2

1 Mar 2022
Breakthrough SARS-CoV-2 infection peaks at 5 months

Breakthrough SARS-CoV-2 infection peaks at 5 months

28 Feb 2022
The need for a holistic and unbiased approach to develop a more universal vaccine for coronaviruses

The need for a holistic and unbiased approach to develop a more universal vaccine for coronaviruses

28 Feb 2022
Vaccination reduces risk of long-COVID

Vaccination reduces risk of long-COVID

27 Feb 2022
A promising new vaccine for SARS-CoV-2 and influenza

A promising new vaccine for SARS-CoV-2 and influenza

27 Feb 2022

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback